JP2024543019A5 - - Google Patents
Info
- Publication number
- JP2024543019A5 JP2024543019A5 JP2024525726A JP2024525726A JP2024543019A5 JP 2024543019 A5 JP2024543019 A5 JP 2024543019A5 JP 2024525726 A JP2024525726 A JP 2024525726A JP 2024525726 A JP2024525726 A JP 2024525726A JP 2024543019 A5 JP2024543019 A5 JP 2024543019A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- cdr1
- cdr2
- cdr3
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163274446P | 2021-11-01 | 2021-11-01 | |
| US202163274449P | 2021-11-01 | 2021-11-01 | |
| US202163274430P | 2021-11-01 | 2021-11-01 | |
| US63/274,449 | 2021-11-01 | ||
| US63/274,446 | 2021-11-01 | ||
| US63/274,430 | 2021-11-01 | ||
| PCT/US2022/079051 WO2023077155A1 (en) | 2021-11-01 | 2022-11-01 | Compositions and methods for the modulation of beta chain-mediated immunity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543019A JP2024543019A (ja) | 2024-11-19 |
| JP2024543019A5 true JP2024543019A5 (enExample) | 2025-11-11 |
Family
ID=84364285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525726A Pending JP2024543019A (ja) | 2021-11-01 | 2022-11-01 | β鎖媒介免疫を調節するための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250092134A1 (enExample) |
| EP (2) | EP4426734A1 (enExample) |
| JP (1) | JP2024543019A (enExample) |
| KR (1) | KR20240099397A (enExample) |
| CN (1) | CN119390841A (enExample) |
| AU (1) | AU2022377084A1 (enExample) |
| CA (1) | CA3237038A1 (enExample) |
| IL (1) | IL312464A (enExample) |
| MX (1) | MX2024005336A (enExample) |
| WO (1) | WO2023077155A1 (enExample) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| CN119954959A (zh) * | 2019-03-11 | 2025-05-09 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
-
2022
- 2022-11-01 EP EP22813861.6A patent/EP4426734A1/en active Pending
- 2022-11-01 CN CN202411513821.5A patent/CN119390841A/zh active Pending
- 2022-11-01 WO PCT/US2022/079051 patent/WO2023077155A1/en not_active Ceased
- 2022-11-01 CA CA3237038A patent/CA3237038A1/en active Pending
- 2022-11-01 MX MX2024005336A patent/MX2024005336A/es unknown
- 2022-11-01 IL IL312464A patent/IL312464A/en unknown
- 2022-11-01 JP JP2024525726A patent/JP2024543019A/ja active Pending
- 2022-11-01 AU AU2022377084A patent/AU2022377084A1/en active Pending
- 2022-11-01 EP EP24222564.7A patent/EP4524160A3/en active Pending
- 2022-11-01 US US18/706,417 patent/US20250092134A1/en active Pending
- 2022-11-01 KR KR1020247018329A patent/KR20240099397A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515565A5 (enExample) | ||
| JP2021533726A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| JP2021516974A5 (enExample) | ||
| JP2021516973A5 (enExample) | ||
| JP2018510636A5 (enExample) | ||
| JP2021515568A5 (enExample) | ||
| JP2021516975A5 (enExample) | ||
| RU2012119788A (ru) | Связывающие il-1 белки | |
| JP2021516976A5 (enExample) | ||
| US20220340673A1 (en) | Antibody targeting bcma, bispecific antibody, and use thereof | |
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| JP2018533371A5 (enExample) | ||
| JP2021514973A5 (enExample) | ||
| JP2016529882A5 (enExample) | ||
| JP2020511947A5 (enExample) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| RU2009129403A (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| KR20230052309A (ko) | 항-bcma 중쇄-단독 항체 | |
| JP2023548529A5 (enExample) | ||
| JP2017507131A5 (enExample) | ||
| JP2021511387A5 (enExample) | ||
| JP2021525806A5 (enExample) |